Moreover, molecular profile analysis of patients from the randomized phase III AIO-PK0104 study of gemcitabine with or without erlotinib in pancreatic cancer did not demonstrate a correlation between EGFR amplification (18%) or EGFR overexpression (46%) with benefit from erlotinib [11]. Here, EGFR is linked to familial pancreatic carcinoma.